Home
    • Plans Blog Contact
    Bristol-Myers Squibb Company logo

    Bristol-Myers Squibb Company

    BMY
    Last price US$62.09
    Market cap US$117.3b
    12M price change 26.84%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Merck & Company IncMRK Industry peer Eli Lilly and CompanyLLY Industry peer Amgen IncAMGN Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Bristol-Myers Squibb Company Overview

    Industry: Drug Manufacturers General

    Sector: Healthcare

    Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an ora Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Bristol-Myers Squibb Company into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Apr 30, 2026

    Quarterly result summary

    Revenue was $6.2B (+12% YoY); EPS was $6.05 (reported).

    Revenue $6.2B +12% YoY
    EPS $6.05 reported
    R&D expense $2.6B reported
    G&A expense $1.6B reported

    What changed

    • Revenue +12% YoY to $6.2B; EPS reported to $6.05.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Apr 30, 2026 Earnings material PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 30, 2026 Apr 30, 2026 SEC filing 10-K Feb 11, 2026 Earnings material PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED FEBRUARY 5, 2026 Feb 05, 2026 Earnings release PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED FEBRUARY 5, 2026 Feb 05, 2026 Earnings release PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED OCTOBER 30, 2025 Oct 30, 2025 Earnings material PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED OCTOBER 30, 2025 Oct 30, 2025 SEC filing 10-Q Oct 30, 2025 SEC filing 8-K Oct 30, 2025 Earnings release PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED JULY 31, 2025 Jul 31, 2025 Earnings material PRESENTATION MATERIALS OF BRISTOL-MYERS SQUIBB COMPANY DATED JULY 31, 2025 Jul 31, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Bristol-Myers Squibb Company earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers General industry , Merck & Company Inc , Eli Lilly and Company , Amgen Inc are companies with high ratings.

    Return on Equity

    Score 1.44/5
    Bristol-Myers Squibb Company exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Bristol-Myer... BMY US$117.3b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.76/5
    Bristol-Myers Squibb Company commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Bristol-Myer... BMY US$117.3b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers General industry , Merck & Company Inc , Eli Lilly and Company , Amgen Inc are companies with high ratings.

    Leverage

    Score 1.42/5
    Bristol-Myers Squibb Company registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Bristol-Myer... BMY US$117.3b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Bristol-Myers Squibb Company logo

    Bristol-Myers Squibb Company

    US$62.09

    US$80.23

    +29.2% vs price

    US$117.3b

    2.22%

    26.84%